340 related articles for article (PubMed ID: 32487686)
21. Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery.
Altman AD; Nelson G; Chu P; Nation J; Ghatage P
J Obstet Gynaecol Can; 2012 Jun; 34(6):558-566. PubMed ID: 22673172
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
23. Laparoscopic Assessment to Determine the Likelihood of Achieving Optimal Cytoreduction in Patients Undergoing Primary Debulking Surgery for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Andikyan V; Kim A; Gretz HF; Zakashansky K; Prasad-Hayes M; Beddoe AM; Dottino P; Mandeli J; Chuang L
Am J Clin Oncol; 2018 Oct; 41(10):938-942. PubMed ID: 29624506
[TBL] [Abstract][Full Text] [Related]
24. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J; Wilhelm-Benartzi C; Yazbek J; Williamson R; Bharwani N; Stewart V; Carson I; Hird E; McIndoe A; Farthing A; Blagden S; Ghaem-Maghami S
BJOG; 2015 May; 122(6):843-849. PubMed ID: 25132394
[TBL] [Abstract][Full Text] [Related]
25. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
26. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
27. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
Sørensen SM; Schnack TH; Høgdall C
Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
[TBL] [Abstract][Full Text] [Related]
28. Assessment of intraoperative tube thoracostomy after diaphragmatic resection as part of debulking surgery for primary advanced-stage Müllerian cancer.
Kato K; Tate S; Nishikimi K; Shozu M
Gynecol Oncol; 2013 Oct; 131(1):32-5. PubMed ID: 23891788
[TBL] [Abstract][Full Text] [Related]
29. Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402).
Hirakawa T; Minaguchi T; Itani Y; Kasamatsu Y; Murase S; Sakurada S; Nagano H; Takehara K; Tsuruta T; Arakawa A; Kawano K; Tsubamoto H; Ushiwaka T; Mori T; Iwai K; Saito M; Morisawa H; Saito F; Yoshida K; Kaneuchi M; Sato H; Ito K; Nasu K
World J Surg Oncol; 2017 Jul; 15(1):132. PubMed ID: 28716033
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
31. Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall.
Nishikimi K; Tate S; Matsuoka A; Shozu M
Int J Clin Oncol; 2019 Aug; 24(8):941-949. PubMed ID: 30891652
[TBL] [Abstract][Full Text] [Related]
32. [Residual Disease Status after Primary Cytoreductive Surgery in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Carcinoma and Long-Term Progression-Free Survival].
Otsuka I; Matsuura T
Gan To Kagaku Ryoho; 2016 Dec; 43(13):2547-2551. PubMed ID: 28028263
[TBL] [Abstract][Full Text] [Related]
33. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
34. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.
Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Mironov S; Iyer RB; Zhou Q; Iasonos A; Paul H; Hosaka M; Aghajanian CA; Leitao MM; Gardner GJ; Abu-Rustum NR; Sonoda Y; Levine DA; Hricak H; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):455-61. PubMed ID: 25019568
[TBL] [Abstract][Full Text] [Related]
35. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
36. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer.
Zeppernick F; Meinhold-Heerlein I
Arch Gynecol Obstet; 2014 Nov; 290(5):839-42. PubMed ID: 25082067
[TBL] [Abstract][Full Text] [Related]
37. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
Cordeiro Vidal G; Babin G; Querleu D; Guyon F
Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
39. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
Peiretti M; Zanagnolo V; Aletti GD; Bocciolone L; Colombo N; Landoni F; Minig L; Biffi R; Radice D; Maggioni A
Gynecol Oncol; 2010 Nov; 119(2):259-64. PubMed ID: 20800269
[TBL] [Abstract][Full Text] [Related]
40. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Shih KK; Chi DS; Barakat RR; Leitao MM
Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
